Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a …
Over the last 12 months, insiders at Vor Biopharma Inc. have bought $0 and sold $20,357 worth of Vor Biopharma Inc. stock.
On average, over the past 5 years, insiders at Vor Biopharma Inc. have bought $73.63M and sold $5.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,979,566 shares for transaction amount of $53.63M was made by RA CAPITAL MANAGEMENT, L.P. () on 2021‑02‑09.
2024-06-03 | Sale | CHIEF MEDICAL OFFICER | 14,645 0.0209% | $1.39 | $20,357 | -35.87% | ||
2021-11-16 | Sale | 330,706 0.7914% | $15.30 | $5.06M | -69.06% | |||
2021-11-16 | Sale | 10 percent owner | 330,706 0.7914% | $15.30 | $5.06M | -69.06% | ||
2021-02-09 | 2.98M 5.6047% | $18.00 | $53.63M | -63.24% | ||||
2021-02-09 | 555,555 1.045% | $18.00 | $10M | -63.24% | ||||
2021-02-09 | 10 percent owner | 555,555 1.045% | $18.00 | $10M | -63.24% |
RA CAPITAL MANAGEMENT, L.P. | 8297265 12.0822% | $0.81 | 1 | 0 | <0.0001% | |
PARMAR KUSH | 1766634 2.5725% | $0.81 | 1 | 1 | <0.0001% | |
5AM Ventures VI, L.P. | 10 percent owner | 1766634 2.5725% | $0.81 | 1 | 1 | <0.0001% |
RA Capital Management, L.P. | $53.91M | 33.33 | 22.75M | 0% | +$0 | 0.05 | |
Fidelity Investments | $18.03M | 11.15 | 7.61M | -0.14% | -$24,906.33 | <0.01 | |
Paradigm BioCapital Advisors LP | $15.3M | 9.46 | 6.46M | 0% | +$0 | 0.56 | |
5Am Venture Management Llc | $15.08M | 9.32 | 6.36M | 0% | +$0 | 1.01 | |
Laurion Capital Management LP | $7.54M | 4.66 | 3.18M | 0% | +$0 | 0.05 |